Clinical trial
A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy
NCT04824924 is registered in ClinicalTrials.gov with Shanghai Jiao Tong University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 31, 2021
- Completion date
- March 31, 2024
- Enrollment
- 100 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.